Befejeződött1. fázis
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
Key facts
- Where
- Badalona, Barcelona, Cáceres, Madrid, Murcia, Santiago de Compostela, Sevilla, Valencia és Zaragoza, SpanyolországSee the 12 sites
- Phase
- 1. fázis
Where in Spanyolország
- Institut Catala d'OncologiaBadalona, SpanyolországNo longer taking part
- Hospital de la Santa Creu i Sant PauBarcelona, SpanyolországNo longer taking part
- Hospital Universitari Vall d'HebronBarcelona, SpanyolországNo longer taking part
- Hospital San Pedro De AlcántaraCáceres, SpanyolországNo longer taking part
- Hospital Universitario Fundación Jiménez DíazMadrid, SpanyolországNo longer taking part
- University Clinical Hospital Virgen De La ArrixacaMurcia, SpanyolországNo longer taking part
- Complexo Hospitalario Universitario De SantiagoSantiago de Compostela, SpanyolországNo longer taking part
- Hospital Universitario Virgen De La MacarenaSevilla, SpanyolországNo longer taking part
- University Hospital Virgen Del Rocio S.L.Sevilla, SpanyolországNo longer taking part
- Fundación Instituto Valenciano de OncologíaValencia, SpanyolországNo longer taking part
- Hospital Universitario Y Politecnico La FeValencia, SpanyolországNo longer taking part
- Hospital Unviersitario Miguel ServetZaragoza, SpanyolországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- H e x a l AG
- Trial code
- EU 2023-506881-30-00
- Record updated
- 2025. november 10.